Q2 2026 saw 16% net sales growth, record wound management performance, and strengthened global partnerships. Adjusted EBITDA rose to SEK 5.6 million, with improved cash flow and continued investment in regulatory and business development initiatives.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.